Harrow (NASDAQ:HROW) Coverage Initiated by Analysts at Cantor Fitzgerald

Cantor Fitzgerald assumed coverage on shares of Harrow (NASDAQ:HROW - Free Report) in a research report released on Friday, Marketbeat Ratings reports. The brokerage issued an overweight rating and a $76.00 price target on the stock.

Several other analysts have also recently commented on HROW. BTIG Research assumed coverage on Harrow in a report on Thursday, June 12th. They issued a "buy" rating and a $62.00 price target for the company. B. Riley reduced their price target on Harrow from $69.00 to $65.00 and set a "buy" rating for the company in a report on Tuesday, April 1st. HC Wainwright raised their price target on Harrow from $57.00 to $60.00 and gave the company a "buy" rating in a report on Monday, May 12th. Finally, William Blair began coverage on Harrow in a research note on Tuesday, June 10th. They issued an "outperform" rating for the company. Seven investment analysts have rated the stock with a buy rating, Based on data from MarketBeat, the stock has a consensus rating of "Buy" and an average price target of $63.83.

Harrow Stock Performance

Harrow stock traded up $0.69 during mid-day trading on Friday, reaching $35.62. 694,283 shares of the company were exchanged, compared to its average volume of 498,252. Harrow has a twelve month low of $20.85 and a twelve month high of $59.23. The firm's 50-day simple moving average is $29.03 and its two-hundred day simple moving average is $28.74. The company has a debt-to-equity ratio of 2.01, a quick ratio of 0.85 and a current ratio of 0.91. The firm has a market cap of $1.31 billion, a PE ratio of -63.61 and a beta of 0.41.

Harrow (NASDAQ:HROW - Get Free Report) last posted its quarterly earnings results on Thursday, May 8th. The company reported ($0.38) EPS for the quarter, missing the consensus estimate of $0.02 by ($0.40). The business had revenue of $47.83 million during the quarter, compared to analyst estimates of $57.00 million. Harrow had a negative net margin of 10.19% and a negative return on equity of 25.01%. Equities analysts predict that Harrow will post -0.53 earnings per share for the current fiscal year.

Hedge Funds Weigh In On Harrow

Several hedge funds have recently bought and sold shares of the stock. Bank of New York Mellon Corp boosted its holdings in shares of Harrow by 8.4% during the fourth quarter. Bank of New York Mellon Corp now owns 86,447 shares of the company's stock worth $2,900,000 after purchasing an additional 6,690 shares during the last quarter. Charles Schwab Investment Management Inc. lifted its stake in shares of Harrow by 1.4% during the fourth quarter. Charles Schwab Investment Management Inc. now owns 255,218 shares of the company's stock worth $8,563,000 after purchasing an additional 3,589 shares in the last quarter. AlphaQuest LLC lifted its stake in shares of Harrow by 452.8% during the fourth quarter. AlphaQuest LLC now owns 3,527 shares of the company's stock worth $118,000 after purchasing an additional 2,889 shares in the last quarter. HighTower Advisors LLC lifted its stake in shares of Harrow by 13.8% during the fourth quarter. HighTower Advisors LLC now owns 10,127 shares of the company's stock worth $340,000 after purchasing an additional 1,227 shares in the last quarter. Finally, Great Lakes Advisors LLC purchased a new stake in shares of Harrow during the fourth quarter worth about $972,000. Hedge funds and other institutional investors own 72.76% of the company's stock.

Harrow Company Profile

Harrow, Inc operates as an ophthalmic-focused healthcare company. The company owns ImprimisRx, an ophthalmology outsourcing and pharmaceutical compounding business. The company was formerly known as Imprimis Pharmaceuticals, Inc and changed its name to Harrow Health, Inc in December 2018. Harrow Health, Inc was incorporated in 2006 and is headquartered in Nashville, Tennessee.